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ABSTRACT 
Background: Previous studies have reported up to 50% of ductal carcinoma in situ (DCIS), is HER2 
positive, but the frequency of HER2 positive invasive breast cancer (IBC) is lower. The aim of this 
study is to characterise HER2 status in DCIS and assess its prognostic value. 
 
Methods: HER2 status was evaluated in a large series of DCIS (n=868) including pure DCIS and 
DCIS associated with IBC, prepared as Tissue Microarrays (TMAs). HER2 status was assessed using 
immunohistochemistry (IHC) and chromogenic in situ hybridisation (CISH). 
 
Results: In pure DCIS, HER2 protein was over-expressed in 9% of DCIS (3+), whereas 15% were 
HER2 equivocal (2+). Using CISH, the final HER2 status was positive in 20%. In mixed DCIS, HER2 
amplification of the DCIS component was detected in 15% with amplification in the invasive 
component of only 12%. HER2 positive DCIS was associated with features of aggressiveness 
(p<0.0001) and more frequent local recurrence (p=0.03). On multivariate analysis, combined 
HER2+/Ki67+ profile was an independent predictor of local recurrence (p=0.006). 
 
Conclusions: The frequency of HER2 positivity in DCIS is comparable to IBC and HER2 positive 
DCIS is associated with features of poor prognosis. The majority of HER2 over-expression in DCIS is 
driven by gene amplification. 
  
  
 
INTRODUCTION 
 
Ductal carcinoma in situ (DCIS) of the breast was less common before the 1980s; however, with the 
introduction of mammographic screening, the incidence has increased dramatically and now comprise 
approximately 20% of breast cancers 1. Over the last decade, breast carcinoma in situ incidence rates 
have increased by almost half (46%) in the UK (http://www.cancerresearchuk.org/health-
professional/cancer-statistics). The mortality from DCIS is very low, with a maximum of 3% at 20 
years of follow-up and the survival after surgery is excellent 2. 
Following a diagnosis of DCIS, women are at elevated risk for disease progression 3, but not all DCIS 
cases progress to invasive carcinoma if untreated with an estimated risk in the range of 25–50% 4. 
Therefore, the main aim of DCIS management is to prevent progression and local recurrence, 
particularly invasive recurrence 5. 
Clinicians are unable to precisely predict the risk of local recurrence or progression to invasive cancer 
in patients with DCIS following their treatment, a major concern that needs to be addressed. 
Treatment is by mastectomy, or lumpectomy with or without adjuvant radiotherapy 6. Factors such as 
young patient age, large tumour size 7, positive margins, comedo necrosis, and high nuclear grade 8 
are associated with a higher risk of recurrence with some emerging data suggesting that ERBB2-
amplified (HER2) DCIS could present a higher risk of recurrence 9. The Van Nuys Prognostic Index 
(VNPI) is a popular risk assessment tool combining patient age, lesion size, nuclear grade and margin 
status for treatment decisions 10. 
HER2 is an established negative prognostic factor in invasive breast cancer 11. The prognostic 
significance of HER2 status in DCIS is, however, less clear 1, 12. The relationship of HER2 to risk of 
recurrence and its role in the progression from in situ to invasive cancer have been debated 9. HER2 
over-expression is reported to be more frequent in DCIS than in invasive cancer 13. This may seem 
contradictory, as HER2 is proposed to play a role in tumour progression. Some studies report an even 
higher proportion of HER2 positivity in micro-invasive cancer 14 and, in preoperative tumour biopsies 
displaying DCIS, HER2 over-expression has been related to increased incidence of invasive 
carcinoma in the surgical specimen 15. Furthermore, HER2 positivity is associated with high 
histopathological grade both in invasive cancer and in DCIS 16. 
Immunohistochemical staining (IHC) can be used as a surrogate marker of gene expression profiling 
in invasive breast cancer, utilising ER, PR, HER2 and Ki-67 protein expression to split patients into 
four different molecular phenotypes 17. Similar subtypes have been found in DCIS, but the prognostic 
significance of grouping DCIS into these subtypes is not yet clear. Some studies have suggested the 
most appropriate treatment could be identified by evaluating individual expression of genes or 
receptors in DCIS 18.  
IHC staining is the predominant method of determining HER2 status in breast cancer specimens due 
to its relative ease to perform with rapid turnaround time and lower cost 19. Although commercially 
  
available antibodies have shown wide variation in sensitivity and specificity for formalin-fixed paraffin 
embedded (FFPE) tissue samples, in which tissue fixation and pre-treatment have a substantial effect 
on staining 20, 21, a significant improvement of the diagnostic standards in clinical histopathology with 
quality control measures were able to improve diagnostic performance in clinical practice 22. 
HER2 gene amplification is primarily detected by in situ hybridisation and uses fluorescence (FISH) to 
detect the signals. This method is expensive and requires expertise with fluorescent microscopy using 
appropriate filters 23. Chromogenic in situ hybridisation (CISH) offers an alternative method, and whilst 
it utilises in situ hybridisation technology of FISH, it takes advantage of a chromogenic signal 
detection that is assessed using light microscopy and therefore costs much less than FISH. CISH is 
able to detect HER2 gene amplification and to minimise, if not eliminate, the borderline category with 
IHC 24. The performance of CISH in HER2 testing has rarely been tested in series, so we aimed to 
characterise HER2 status using IHC and CISH in DCIS and assess its prognostic value in a large and 
well annotated cohort. 
 
PATIENTS AND METHODS 
Study Cohort and Tissue Microarray 
This retrospective study was conducted on a consecutive series of primary pure DCIS cases 
diagnosed, and treated, between 1990 and 2012 at Nottingham City Hospital, Nottingham, UK. 
Exclusion of referral, miscoded and recurrent cases resulted in 776 cases of pure primary DCIS with 
available formalin-fixed paraffin embedded (FFPE) tumour blocks for TMA construction. During the 
same time period, a series of 239 cases diagnosed as synchronous DCIS and invasive tumours 
(mixed DCIS and IBC) was also collected for comparison. Patients’ demographic information, 
histopathological parameters, surgical management, radiotherapy and patient outcome data were 
collated. Tumour size was the sum of the primary excision and the re-excision tumour size (mm). 
Tumour grade was classified according to the three-tier nuclear grading system; low, intermediate and 
high nuclear grades 25. Local recurrence free survival (LRFS) was calculated based on the time (in 
months) from the date of primary surgical treatment to the time of ipsilateral local recurrence. Patients 
who developed contralateral disease following DCIS diagnosis were censored at the time of diagnosis 
of the contralateral cancer. 
The median follow-up period in the pure DCIS cohort treated with breast conserving surgery was 118 
months (range 2 to 240 months), during which 75 patients (12%) developed ipsilateral local 
recurrence including invasive carcinoma in 48 (62%). Of the 308 patients treated with breast 
conserving surgery alone, there were 67 recurrences (22%), of which 38 (57%) cases were invasive 
recurrences. Among the 93 cases treated with breast conserving surgery and radiotherapy, there 
were 8 recurrences (9%) (two invasive and six DCIS). 
 
  
Tissue microarrays (TMAs) were prepared from representative DCIS lesions of the pure cases and 
from DCIS and invasive tumours from the mixed cases as previously described 26. The TMA was 
constructed using 3D Histech® Grand Master®, Budapest, Hungary, whereby representative cores of 1 
mm and 0.6 mm from appropriate viable tumour area were taken from DCIS and invasive tumour 
samples respectively, avoiding scanty, single focus, necrotic tumour zones and thinner tumour blocks 
than 4 mm. Each case was represented by a single core biopsy; however, cases with more than one 
histologic tumour type were represented by more than one core. 
 
Immunohistochemistry and Chromogenic in Situ Hybridisation 
The expression of ER, PR, HER2 and Ki67 was evaluated using IHC on the TMA sections. Positive 
and negative controls were included in every assay (supplementary material). MIB1 antibody was 
used for evaluation of Ki67 expression. Nuclear staining was scored for ER, PR and Ki67 and 
membrane staining for HER2. HER2 status was assessed using HercepTest scoring method 27 where 
0 (no membrane staining or incomplete staining of < 10% of cells), 1+ (weak or moderate incomplete 
membrane staining of > 10% cells), 2+ (strong, complete membrane staining in ≤10% of tumour cells 
or weak/moderate complete membrane staining in ≥10% of tumour cells), or 3+ (strong, complete 
membrane staining in >10% of tumour cells). HER2 status was considered negative if the 
immunohistochemical score was 0 or 1+, equivocal if the score was 2+, and positive if the score was 
3+.  
In equivocal cases, HER2 gene amplification was determined by chromogenic in situ hybridisation 
(CISH). This was performed using the ZytoDot 2C SPEC ERBB2/CEN 17 Probe Kit, Germany. 
Interpretation of CISH was performed using a Nikon microscope equipped with a x63 objective lens. 
At least 20 malignant, non-overlapping cell nuclei were scored to assess HER2 gene copy number. 
Chromosome 17 (represented by the red signals) was used as an internal control particularly in the 
low HER2 gene copy number cases as per the recommended protocol. HER2 gene amplification was 
defined as six or more signals per nucleus or when clusters (clumps of aggregated green signals) 
were identified in the cell nuclei in more than 50% of tumour cells 28. If the average copy number was 
≥4 to <6 per nucleus (equivocal), another 20 tumour cells were enumerated, and the final average 
copy number of the case was calculated from the total of 40 cells. In cases with multiple cores (n=26), 
HER2 score was initially obtained by IHC followed by confirmation with CISH to reach the final status 
of the case (Supplementary table 1).  
 
For ER and PR, a 1% cut-off value was used to dichotomise cases into positive and negative 29. For 
Ki67 the cut-off for differentiating low and high proliferative groups was 14% 30. 
 
Statistical analysis: 
Statistical analyses were performed using SPSS v24 (Chicago, IL, USA) for windows. Association 
between final HER2 status and clinicopathological parameters using categorised data in the pure 
DCIS cohort was evaluated using Chi-squared test. Survival rates were determined using the Kaplan–
Meier method and compared by the log-rank test. Multivariate survival analyses using Cox 
  
proportional hazard regression model was used to evaluate the associations between independent 
variables and local recurrence. Multivariable hazards ratio and their corresponding 95% confidence 
intervals (CI) were initially performed for each marker alone and then for the combination of 
biomarkers. All tests were 2-tailed and a p value of less than 0.05 was considered as statistically 
significant. 
 
 
RESULTS 
 
A total of 651 cases of pure DCIS patients (Supplementary Table 2) and 217 cases mixed with 
invasive carcinoma were suitable for analysis.  When pure DCIS was compared to DCIS mixed with 
invasive disease, mixed DCIS was of higher nuclear grade with comedo necrosis (p<0.0001). 
 
Assessment of HER2 status  
In the pure DCIS group, 20% of cases were HER2 positive. Immunohistochemistry for HER2 was 
scored as 3+ in 9%, 2+ in 15% and 0 or 1+ in 76% (Table 1). All 3+ cases showed HER2 
amplification with CISH. 73% of 2+ cases showed HER2 amplification (4 cases in which CISH could 
not be assessed due to technical issues and were excluded) (Figure 1). CISH confirmed high copy 
number of HER2 gene in all IHC 3+ cases. Of the 493 cases with 0/1+ score using IHC, only one 
case showed HER2 amplification. When IHC results were assessed with the exclusion of equivocal 
(2+) tumours, agreement between IHC and CISH in 0, 1+ and 3+ cases was 99.7% (?-coefficient = 
0.997) (Table 1 and Supplementary Table 3). Interestingly, when the overall rate of positivity was 
analysed over the period of the study, the frequency of positivity reduced from 30% in the 1990s to 
20% in 2012 (Figure 2). 
 
Twenty-six cases had multiple cores across the TMAs, of which 15 were concordant for IHC and 
CISH (13 for IHC 0/1+ and 2 for IHC 2+). Of the 11 cases with discordant IHC, which included all 
possible pairwise combinations of 0/1+, 2+ and 3+, the CISH results were consistent across the 
cores, indicating a greater reliability of CISH over IHC in detecting true amplification particularly in 
heterogeneous cases as well as in limited samples such as core biopsies. 
 
In mixed DCIS and invasive carcinoma cases, the DCIS component was HER2 positive in 15% and 
the invasive component in 12% (p=0.051, Table 2 and Supplementary Tables 4 to 7). All 8 
discordant cases had extensive DCIS; 6 of them were of high grade and ER positive.  
 
Correlation with clinicopathological parameters and molecular biomarkers 
In pure DCIS, HER2 positivity was associated with larger tumour size, high nuclear grade, comedo 
type DCIS, negative hormone receptor status, high Ki67 proliferation index and abnormal expression 
of p53 (all p<0.0001). HER2 positive cases were more frequent in patients treated by mastectomy 
(p=0.001) (Table 3). 
  
 
Associations with outcome 
Nuclear grade, comedo necrosis and margin width were individually associated with the development 
of all ipsilateral recurrences (p=0.023, 0.013, 0.029 respectively). When recurrences were stratified 
into in situ and invasive recurrences, HER2 was associated with the development of DCIS local 
recurrence. Patients with HER2+/Ki67-high DCIS had a high likelihood of developing invasive local 
recurrence (p=0.004). On multivariable analysis, patients with HER2+/Ki67-high DCIS had a hazard 
ratio of 2.5 (95% CI: 1.7 – 55.0, p=0.006), compared to women with other profiles. (Table 4).  
 
DISCUSSION 
 
HER2 status can be detected by analysing the number of gene copies or measuring the amount of 
protein expression. The most widely used methods at present are IHC, FISH and CISH due to their 
propensity in evaluating HER2 in formalin-fixed paraffin-embedded (FFPE) tissues in invasive 
carcinoma 31. Most HER2 studies have been performed by IHC, which is widely accessible, easy to 
perform at a reasonable cost and is appropriate for initial HER2 assessment 32. However, in cases 
with an IHC score of 2+, the inter-observer agreement is poor, and the predictive value is 
unsatisfactory for clinical use. This led to the recommendation of additional testing measuring HER2 
gene copy number status using an in situ hybridisation technique such as FISH or CISH to avoid 
inaccurate prognostication and inappropriate treatment 32, 33.  
Although FISH is a fairly objective and quantitative procedure in detecting HER2 gene amplification, it 
has many drawbacks including its cost, the essential need for a fluorescence microscope, its 
temporary signal which requires a special camera, and is technically challenging with TMA 
preparations 34. CISH is an alternative in situ hybridisation method to analyse gene amplification 35. It 
requires an ordinary bright field microscope and the method is less cumbersome and more 
economical with permanent signal intensity. Pathologists are able to correlate findings with the 
underlying tumour histo-morphology. Furthermore, several studies have demonstrated good 
correlation between CISH and FISH results 36, 37. CISH is either performed as dual colour or single 
colour with an advantage of the latter over the former in being easy to count signals especially in 
amplified cases 38. 
To the best of our knowledge, this is the first study to assess HER2 in DCIS using in situ 
hybridisation. In this study, similar to a previous study, but in invasive tumour 31, the concordance 
between 3+ IHC and CISH-amplified cases was 100%, denoting all HER2 over-expressing cases as 
having HER2 gene amplification. In contrast, the proportion of 2+ IHC that were HER2 amplified, as 
detected by CISH, was 73.5%, which is lower than previously reported (93%) 39. The 26.5% (26/98) 
IHC-equivocal/HER2 non-amplified tumours in this study, all of which had 2+ IHC scores, is higher 
than the result obtained by other studies on invasive tumours 40-42. The concordance between 0/1+ 
IHC and HER2 non-amplified tumours was 99.7%. A similar finding was reported by Zhao and 
colleagues and they considered that there is a small undetermined percentage of amplified HER2 
without protein over-expression 40. The same study and other FISH studies on invasive carcinoma 
  
also reported rare 3+ IHC tumours that were non-amplified 40-43, however, we did not detect any such 
cases. 
The low-amplified HER2 category (≥ 4 to <6 CISH signals) was the most difficult to interpret, requiring 
an accurate enumeration of gene copy and addition of more tumour cells to assess the final status. 
This step was particularly important because these cases could either resolve as amplified (4/7) or 
non-amplified (3/7). Signal clustering, more probably a result of intra-chromosomal amplification of 
homogeneously staining regions, was immediately evident in highly amplified cases and was easily 
evaluated. 
We observed a lower HER2 expression in DCIS compared to the previously published literature 1, 15. 
This might be related to the increasing detection of low and intermediate grade DCIS by screening 
mammography. In support of this the HER2 positivity was higher (30%) in the earlier period of the 
study and declined over time to 20%. (Figure 2).  
The question of whether or not TMA cores are representative of whole tumours is frequently raised, 
as some tumours are heterogeneous and so a small sample of tissue may not always display the 
same biological characteristics as a larger section 34. To increase the credibility of the TMA technique 
while reducing the probability of error associated with the difficulty of obtaining a representative 
sample, some studies use multiple cores from the same donor tissues as it has been reported that 
only a few (up to four) cores are required to achieve a 100% agreement 44. However, even when as 
many as 10 tissue cores are taken from a tumour, some disagreement may be noted 45, 46. In the 
current study, 1 mm diameter cores were used to construct the TMA of the pure DCIS tumours, 
increasing the probability of accurate sampling by taking large TMA cores. In cases with multiple 
cores, the initial HER2 status was assessed at the protein level followed by confirmation with in situ 
hybridisation. The high agreement rate between IHC and CISH results suggests that it is possible to 
apply TMAs to DCIS research, with the caveat that, for HER2, the CISH results may be more reliable, 
countering the discrepancy that can be observed in IHC for either technical or biological reasons.  
Our subsequent goal in this study was to assess the role of HER2 in progression of DCIS. HER2 
positive DCIS was associated with predictors of local recurrence like larger tumour size, high nuclear 
grade, comedo type DCIS, negative hormone receptor status and high Ki67 proliferation index, which 
was consistent with other studies 12, 47-51. Local recurrence (invasive or DCIS) was associated with 
higher grade, comedo necrosis and margin status. DCIS local recurrence was associated with HER2 
positivity and invasive local recurrence was associated with tumour size.  Similar to some studies, 
HER2 positive tumours were associated with DCIS local recurrence 52, 53.  
DCIS patients with HER2 amplification had higher nuclear grade lesions and therefore are probably at 
risk of relapse more frequently than the HER2 unamplified group, but the prognostic role of HER2 
over-expression in DCIS is still not fully clarified. Some studies suggest that patients with HER2 
amplified DCIS are more frequently high nuclear grade and this aspect is related to an increased risk 
of relapse 54, 55. In fact, some studies suggest that HER2 plays a major role in the transition from DCIS 
  
to IDC 18, 56, while others do not support this 9, 57. In the current study, HER2 amplification was more 
frequent in the pure DCIS cohort (20%) than in the mixed DCIS (15%) despite the more prevalent 
higher-grade DCIS in the mixed cases. HER2 positivity alone was not predictive of recurrence as a 
whole or as invasive disease but showed a trend to DCIS recurrence. This result is consistent with our 
observation that HER2 positive DCIS tend to extend within the ductal system and even in the 
epidermis (Paget’s disease) than associated with invasive disease. It is our personal observation that 
when HER2 positive DCIS is associated with early invasion, that invasive disease may show 
aggressive features. Currently HER2 positive invasive tumours are treated more aggressively 
regardless of its size 58. This may suggest that HER2 positive DCIS tumour cells although highly 
proliferative are not highly invasive, whilst those that acquire invasive properties became aggressive 
and can metastasise.    
In order to improve the risk stratification and therefore treatment recommendations, there is a need to 
identify potential predictors of invasive and/or non-invasive recurrence following conserving breast 
surgery. HER2/Ki67 positivity was a predictor of recurrence, independent of other studied 
clinicopathological parameters such as nuclear grade and presence of comedo necrosis. In contrast 
to a previous study 59, the combination of ER status with HER2 and Ki67 further added additional 
predictive information. This difference may be due to the differences in patient populations, or to 
differences in the coding of HER2 positivity. The previous study coded DCIS lesions with equivocal 
immunostaining for HER2 (score of 2+) as positive. We performed in situ hybridisation on all 
equivocal cases and only lesions with amplification were coded as HER2 positive. 
 
In the present study, HER2 expression in the invasive component was seen less frequently as 
compared to the DCIS component adjacent to invasive carcinoma and pure DCIS although this was of 
borderline statistically significant. Similarly, other studies 54, 60 have observed that HER2 positivity is 
often in patients with pure DCIS compared to those with microinvasive or invasive carcinoma. As it 
has been reported that patients with HER2+ invasive cancer have a poorer prognosis than those 
whose tumours do not express HER2 61, the higher incidence of expression found in DCIS may 
therefore seem paradoxical. It was postulated that HER2 expression happens during the process of 
atypical hyperplasia in DCIS, and loss of HER2 expression occurs as DCIS develops into invasive 
disease. Another hypothesis is that HER2 overexpression in invasive carcinoma does not develop 
from DCIS but from the associated atypical hyperplasia 62, 63. Another theory explaining this 
phenomenon is that most invasive cancers develop from DCIS tumours which have low expression of 
HER2 but are highly proliferative 54. Because such tumours progress rapidly, they are in the DCIS 
stage for only a short period and would therefore be under-represented in population samples 54.  
In summary, CISH is a promising, practical test that can be used in conjunction with IHC to determine 
HER2 status in DCIS. IHC is easy to perform, relatively inexpensive, and able to detect a majority of 
breast cancer patients whose tumours have negative (0 or 1+) or positive (3+) HER2 status. This 
IHC/CISH test stratification not only identifies the IHC borderline cases, but also keeps testing costs 
  
for HER2 status at a reasonable minimum. As HER2 status is not currently routinely measured in 
clinical practice, we aimed to show statistically significant correlations between the development of 
local recurrence as well as poor prognostic pathologic factors and HER2 positive DCIS which could 
alert clinicians. Our results might suggest considering routine assessment of HER2 in DCIS, similar to 
invasive breast cancer. 
We also confirmed the suitability of the TMA technique for assessment of HER2 gene amplification 
status in tumours arising from different patients, while maintaining a representative tissue sample in 
each case, with good reproducibility and credible results. 
To conclude, the frequency of HER2 positivity, driven by gene amplification, in DCIS is comparable to 
IBC and in combination with Ki67, is an independent predictor of recurrence. Our results suggest the 
consideration of routine assessment of HER2 status for DCIS, as it is commonly done for IBC. 
Limitations of the study 
This study has been conducted on TMA sections, which might underestimate the role of tumour 
heterogeneity. However, all cases in our cohort were carefully reviewed before TMA construction and 
used multiple cores for cases with heterogeneous morphology. The lower number of radiotherapy-
treated cases after BCS was due to the prevalence of mastectomy in the earlier period of the study; 
which constituted the majority of cases.  
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Figure 1: (A and B) DCIS showing HER2 3+ (A) confirmed by CISH (B), (C and D) HER2 2+ (C) 
showing gene amplification (D), (E and F) HER2 2+ (E) without amplified gene (F), and (G and H) 
HER2 1+ (G) showing no gene amplification (H). 
 
Figure 2: The rate of HER2 positivity, grade and screen detected DCIS change over time. The graph 
shows that the rate of high grade DCIS together with HER2 positivity is declining over years in 
contrast to the rate of screen detected DCIS. 
 


Table 1: HER2 status in pure DCIS cases using IHC and CISH 
CISH HER2 IHC in pure DCIS 
0/1+ (n=493) (%) 2+ (n=98) (%) 3+ (n=56) (%) Total (n=647) (%) 
Amplified 1 (0.2) 72 (73.5) 56 (100.0) 129 (20.0) 
Non-amplified 492 (99.8) 26 (26.5) 0 (0.0) 518 (80.0) 
 
DCIS: Ductal carcinoma in situ, IHC: Immunohistochemistry, CISH: Chromogenic in situ hybridisation. 
 
Table 2: HER2 status in DCIS cases mixed with invasion 
A) HER2 status in DCIS cases mixed with invasion using IHC and CISH. 
CISH HER2 IHC DCIS Component HER2 IHC Invasive Component 
1+ (n=185) (%)  2+ (n=10) (%) 3+ (n=22) (%) Total (n=217) 
(%) 
1+ (n=192) (%) 2+ (n=2) 
(%) 
3+ (n=23) (%) Total (n=217) 
(%) 
Amplified 5 (2.7) 5 (50.0) 22 (100.0) 32 (14.7) 1 (0.5) 1 (50.0) 23 (100.0) 25 (11.5) 
Non-amplified 180 (97.3) 5 (50.0) 0 (0.0) 185 (85.3) 191 (99.5) 1 (50.0) 0 (0.0) 192 (88.5) 
 
B) Final HER2 status of DCIS and invasive component of DCIS cases mixed with invasion  
 
 Invasive HER2 Total N. (%)
DCIS HER2  Positive Negative
 Negative 1 184 185 (85.3)
 Positive 24 8 32 (14.7)
Total 25 (11.5) 192 (88.5) 217 
 
DCIS: Ductal carcinoma in situ, IHC: Immunohistochemistry, CISH: Chromogenic in situ hybridisation. 
 
Table 3: Association between final HER2 status and the clinico-pathological parameters of 
pure DCIS cohort. 
 
Parameter 
HER2 Status
Total (n=646)
n (%)
Positive (n=128)
n (%)
Negative (n=518) 
n (%)
χ2
(p value)
Age, years* 
   Less than 40 
   Between 40 and 60 
   More than 60 
 
22 (3.4) 
376 (58.2) 
248 (38.4)
 
7 (6) 
74 (58) 
47 (36)
 
15 (3) 
302 (58) 
201 (39) 
 
2.12 
(0.347) 
Presentation 
   Screening 
   Symptomatic 
 
336 (52) 
310 (48)
 
69 (54) 
59 (46)
 
267 (51) 
251 (49) 
 
0.23 
(0.632)
DCIS Size (mm) 
   Less than 16 
   Between 16 and 40 
   More than 40 
 
223 (34.8) 
247 (38.5) 
171 (26.7)
 
27 (22) 
47 (37) 
52 (41)
 
196 (38) 
200 (39) 
119 (23) 
 
20.63 
(<0.0001) 
Nuclear Grade 
   Low 
   Intermediate 
   High 
 
87 (13.5) 
166 (25.7) 
393 (60.8)
 
0 (0) 
13 (10) 
115 (90)
 
87 (17) 
153 (29) 
278 (54) 
 
58.58 
(<0.0001) 
Comedo necrosis 
   Yes 
   No 
 
411 (63.8) 
233 (36.2)
 
111 (87) 
17 (13)
 
300 (58) 
216 (42) 
 
36.28 
(<0.0001)
Management 
   Mastectomy 
   Breast Conserving Surgery 
 
339 (52.5) 
307 (47.5)
 
84 (66) 
44 (34)
 
255 (49) 
263 (51) 
 
11.06 
(0.001)
Radiotherapy 
   Yes 
   No 
 
95 (14.7) 
551 (85.3)
 
19 (15) 
109 (85)
 
76 (15) 
442 (85) 
 
0.002 
(0.961)
Oestrogen Receptor Status 
   Positive 
   Negative 
 
426 (75.3) 
140 (24.7)
 
45 (40) 
66 (60)
 
381 (84) 
74 (16)
 
88.86 
(<0.0001)
Progesterone Receptor Status 
   Positive 
   Negative 
 
302 (46.7) 
344 (53.3)
 
18 (14) 
110 (86)
 
284 (55) 
234 (45) 
 
68.51 
(<0.0001)
Ki67 Index 
   High Proliferative 
   Low Proliferative 
 
108 (23.0) 
361 (77.0)
 
64 (59) 
45 (41)
 
97 (27) 
263 (73) 
 
37.46 
(<0.0001)
 
p value in bold: significant 
DCIS: Ductal carcinoma in situ, n: Number 
*Age: categorised according to the Van Nuys Prognostic Index (VNPI). 
 
Table 4: Univariate and multivariate analysis  
 
A) Univariate analysis for predictors of local recurrence in pure DCIS patients treated with breast 
conserving surgery. 
 
 
 
 
 
 
 
 
Outcome HR (95% CI) P value* 
All local recurrence 
   Tumour size  
   High tumour grade 
   Comedo necrosis 
   Margin width 
   Radiotherapy 
   ER status 
   HER2 status 
   Ki 67 status 
 
1.31 (0.36-2.55) 
3.43 (1.18-9.96) 
3.63 (1.44-7.82) 
0.63 (0.34-0.91) 
0.95 (0.47-1.91) 
1.09 (0.58-2.05) 
0.89 (0.45-1.74) 
2.61 (0.33-5.01) 
 
0.098 
0.023 
0.013 
0.029 
0.890 
0.777 
0.734 
0.089 
DCIS local recurrence 
   Tumour size  
   High tumour grade 
   Comedo necrosis 
   Margin width 
   Radiotherapy 
   ER status 
   HER2 status 
   Ki 67 status 
 
1.01 (0.46-2.23) 
1.90 (0.21-4.72) 
1.24 (0.73-1.99) 
1.83 (0.15-11.96) 
0.75 (0.35-1.59) 
0.76 (0.29-1.92) 
2.51 (2.11-11.45) 
2.44 (0.13-2.29) 
 
0.423 
0.569 
0.372 
0.180 
0.459 
0.551 
0.030 
0.067 
Invasive local recurrence 
   Tumour size  
   High tumour grade 
   Comedo necrosis 
   Margin width 
   Radiotherapy 
   ER status 
   HER2 status 
   Ki 67 status 
 
2.63 (1.13-6.09) 
1.15 (0.25-5.24) 
1.49 (0.814-2.76) 
0.69 (0.43-2.47) 
1.17 (0.35-3.86) 
1.01 (0.45-2.65) 
0.49 (0.17-1.41) 
1.28 (0.41-3.88) 
 
0.024 
0.871 
0.194 
0.578 
0.780 
0.833 
0.184 
0.668 
B) Multivariate Cox proportional hazards for factors associated with local recurrence in pure ductal 
carcinoma in situ patients.  
 
Variable HR 95% CI p-value
Ductal carcinoma in situ size 0.62 0.31-3.47 0.311
Ductal carcinoma in situ Grade 2.21 1.15-70.85 0.031
Comedo necrosis 0.32 0.12-0.87 0.026
Margin width 0.89 0.11-7.46 0.911
HER2+/Ki67-high group 1.52 1.64-60.74 0.001
 
DCIS: Ductal carcinoma in situ, HR: Hazard ratio, CI: Confidence Interval, ER: Oestrogen Receptor,   
*P values are corrected according to Bonferroni multiple testing correction; bold facing is significant. 
 
HR: Hazard ratio, CI: Confidence Interval. 
 
